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Rationale: Lung cancer screening using computed tomography (CT)
is effective indetecting lung cancer in early stages. Concerns regard-
ing false-positive rates and unnecessary invasive procedures have
been raised. Objective: To study the efficiency of a lung cancer
protocol using spiral CT and F-18-fluorodeoxyglucose positron
emission tomography (FDG-PET).Methods:High-risk individuals un-
derwent screeningwith annual spiral CTs. Follow-up CTswere done
for noncalcified nodules of 5mmor greater, and FDG-PETwas done
for nodules 10 mm or larger or smaller ( 7 mm), growing nodules.
Results: A total of 911 individuals completed a baseline CT study
and 424 had at least one annual follow-up study. Of the former,
14% had noncalcified nodules of 5 mm or larger, and 3.6% had
nodules of 10 mm or larger. Eleven non–small cell lung cancers
(NSCLC) and one small cell lung cancer (SCLC) were diagnosed in
the baseline study (prevalence rate, 1.32%), and two NSCLCs in
the annual study (incidence rate, 0.47%). All NSCLCs (92%of preva-
lence cancers) were diagnosed in stage I (12 stage IA, 1 stage IB).
FDG-PET was helpful for the correct diagnosis in 19 of 25 indetermi-
nate nodules. The sensitivity, specificity, positive predictive value,
and negative predictive value of FDG-PET for the diagnosis ofmalig-
nancywere 69, 91, 90, and 71%, respectively. However, the sensitiv-
ity and negative predictive value of the screening algorithm, which
included a 3-month follow-up CT for nodules with a negative FDG-
PET, was 100%. Conclusion: A protocol for early lung cancer detec-
tion using spiral CT and FDG-PET is useful andmayminimize unnec-
essary invasive procedures for benign lesions.
Keywords: chronic obstructive pulmonary disease; lung neoplasm;
pulmonary nodule; smoking
Lung cancer is the most frequent and lethal malignancy in the
world (1–3). Advances in the treatment of locally advanced lung
cancer have had no impact on overall 5-year survival rates from
this disease (1, 2). In countries where gains against tobacco
smoking have been made, mortality rates from lung cancer have
started to decrease, but future projections are not optimistic
because of the recent surge in tobacco consumption among
young people (4). And even if smoking could be reduced signifi-
cantly, the long lag time between peak tobacco consumption
and the development of clinical lung cancer will assure a long
life for this epidemic.
The main reason why more than 80% of patients with lung
cancer die soon after diagnosis is that most patients are diag-
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nosed in late nonsurgical stages (4). Large screening trials have
investigated the use of conventional radiology and sputum cytol-
ogy for early detection of lung cancer but failed to show a
reduction in disease-specificmortality, resulting in public policies
against screening for this disease (5–8). However, recently, very
promising reports using spiral computed tomography (CT) have
brought lung cancer screening back to the forefront. The Early
Lung Cancer Action Project (ELCAP) demonstrated that low-
dose spiral CT detects lung cancer in early stages much more
effectively than conventional chest radiograph (9). Following a
carefully designed protocol based on follow-up CTs to detect
growth of small nodules, 86% of lung cancers diagnosed in
asymptomatic individuals were in stage I (9). Other studies using
spiral CT have found similar results, although with variations
in the percentage of individuals with positive CTs (i.e., with
noncalcified nodules that need further workup) (10–14).
Swensen and colleagues (10) reported noncalcified nodules in
close to 70% of the individuals participating in a lung cancer
screening trial with spiral CT. Diederich and coworkers (11)
found noncalcified nodules in 43%of their population. Although
the ELCAP investigators only performed one invasive proce-
dure on one benign lesion (9), the high prevalence of noncalcified
nodulesmay result in unnecessary invasive procedures for benign
diseases. This will be of particular concern when these protocols
become widely used in the community with less rigorous stan-
dards. Positron emission tomography with the glucose analog
F-18-fluorodeoxyglucose (FDG-PET) is an accurate noninvasive
imaging test for diagnosis of pulmonary nodules, although few
data exist for nodules smaller than 1 cm in diameter (15). Pas-
torino and colleagues (12) showed that selective use of FDG-
PET in a spiral CT-based lung cancer screening trial may be
useful in avoiding biopsies for benign lesions. The hypothesis
formulated in the study presented herein is that adding FDG-
PET to a spiral CT–based early lung cancer detection protocol
will avoid unnecessary procedures for benign lesions. Further-
more, false-negative lesions (i.e., cancers with no pathologic
uptake on the FDG-PET) will be diagnosed with follow-up CTs
to detect growth, and therefore such a protocol will not result
in missed cancers because of negative PET scans.
After publication of their original results, the ELCAP group
led two important initiatives: the NY-ELCAP screening trial, a
New York–area multicenter trial projecting to screen 10,000
high-risk individuals with spiral CT, and the I-ELCAP, an inter-
national consortium that brings together investigators from over
30 centers from around the world (16). One of the main objec-
tives of I-ELCAP is to pool data from screening trials underway
in these centers. The current article presents results from an ongo-
ing trial of lung cancer screening using spiral CT and FDG-PET
conducted at our institution as a member of I-ELCAP since
2000. Some of the results of these studies have been previously
reported in the form of an abstract (17).
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METHODS
Population
Current and former smokers of at least 40 years of age, with a minimum
10 pack-year smoking history, and with no symptoms of lung cancer
were invited to participate. A background questionnaire and written,
informed consent were obtained. The study protocol was approved by
our center’s ethics committee.
CT
CT examinations were done in a single breath-hold at end-inspiration.
The initial 297 subjects were studied with a single-slice helical scanner
(Somatom Plus 4; Siemens, Erlangen, Germany) at low-dose settings
(140 kilovolt peak [kVp], 43 milliampere seconds [mAs]) and 1.5 pitch
with a collimation of 8 mm. Pulmonary nodules were characterized
with a limited high-resolution CT (1-mm slice thickness). For the subse-
quent 614 patients, a four-row multislice helical CT scanner was used
(Somatom Volume Zoom; Siemens, Forchheim, Germany) at a low-
dose setting (120 kVp, 20 mAs, 1.25-mm slice thickness). Studies were
analyzed independently by two radiologists.
Pulmonary Nodules
Calcifications, size, location, edges, and spiculations were documented
for each nodule. Size was the average of length and width and classified
nodules into three categories: less than 5 mm, 5 to but not including
10 mm, and 10 mm or greater.
FDG-PET
Except for nodules with benign characteristics, noncalcified nodules of
10 mm or greater, or smaller nodules ( 7 mm) showing growth, were
evaluated with FDG-PET. Imaging acquisition was performed with a
full ring bismuth germanate (BGO) tomograph (Ecat Exact HR; CTI/
Siemens, Erlangen, Germany). Visual analysis was performed by two
nuclear medicine physicians, and was considered positive for malig-
nancy when focal uptake was observed in the lung nodule. Metabolic
activity was assessed by the maximum standardized uptake value
(SUVmax).
Diagnostic Algorithm
The result of the baseline screening test was considered positive if there
were one to six noncalcified nodules, or more than six nodules with
the largest one being 5 mm or greater. When the initial low-dose CT
study was negative or the initial baseline study did not lead to the
diagnosis of a malignancy, repeat screening was performed after 12
months. A positive study prompted further workup according to an
algorithm developed by I-ELCAP (16). A 3-month follow-up CT was
done for nodules between 5 and 10 mm, and, if growth was detected,
appropriate diagnostic studies were done. If no growth was seen, an
annual CT was scheduled. Growth was assessed visually by the radiolo-
gist comparing two CTs side by side on the workstation. FDG-PET
was done for nodules 10 mm or larger or smaller nodules ( 7 mm)
showing growth, and, if positive, a percutaneous fine needle aspiration
(FNA) or an intraoperative biopsy was performed. For nodules 10 mm
or larger with benign characteristics, a 3-month follow-up CT was done
instead of an FDG-PET.
Spirometry
FVC and FEV1 were measured with a computerized spirometer (Vmax
22; SensorMedics, Yorba Linda, CA). Results were expressed as a
percentage of the predicted value according to the European Commu-
nity Lung Health Survey (18). The presence and severity of airflow
obstruction was determined following the criteria established by the
Global Initiative for Chronic Obstructive Lung Disease (GOLD) (19).
Data Analysis
Normally distributed data were summarized asmeans (SD), and skewed
data were summarized as medians (interquartile range). Data analy-
sis was performed with SPSS for Windows, version 11 (SPSS, Inc.,
Chicago, IL).
RESULTS
Study Population and Risk Factors
A total of 911 (74% men) subjects participated in the study. Their
mean (SD) age was 54.7 (8.6) years. Their median (interquartile
range) tobacco consumption was 30 (19–49.5) pack-years. Asbestos
exposure was reported in only one subject. Other risk factors for
lung cancer, such as radon, nickel, or chromium, were not reported.
Low-Dose CT Findings
In 440 (48.3%) individuals, at least one pulmonary nodule was
observed at baseline examination. Noncalcified nodules of any
size were observed in 291 (31.9%) subjects. At least one non-
calcified nodule of 5 mm or more was found in 131 (14.4%)
subjects. Of the 291 individuals with noncalcified nodules, 164
(56.4%) had one nodule, 70 (24.1%) had two nodules, 31 (10.7%)
had three nodules, 11 (3.8%) had four nodules, and 15 (5.2%)
had five or more nodules.
Nodule Size and Attenuation
A total of 973 nodules were detected on baseline low-dose CT
studies (Table 1). Of these, 434 (44.6%) were homogeneously
calcified nodules and 539 (55.4%) showed no calcification. Of
the 539 noncalcified pulmonary nodules, 369 (68.5%) had amaxi-
mum diameter less than 5 mm, 136 (25.2%) were between 5 and
10 mm, and 34 (6.3%) were 10 mm or larger.
Of the 291 individuals with noncalcified pulmonary nodules,
160 (17.6% of participants) only had nodules less than 5 mm,
98 (10.7% of participants) had at least one nodule between 5
and 10 mm (no nodules 10 mm), and 33 (3.6% of participants)
had at least one nodule of 10 mm or more (Table 2).
FDG-PET for Nodules 10 mm or Larger or Smaller ( 7 mm),
Growing Nodules
Twenty-four FDG-PET scans were done on 23 individuals (25
pulmonary nodules; Table 3). One individual had two FDG-PET
scans (numbers 10 and 16, Table 3) for a nodule that grew from
10.5 to 14.5 mm in 7 months, and turned out to be a malignancy.
The first FDG-PETwas negative (false-negative), but the second
showed an SUVmax of 1.6 (true-positive). Three of the nodules
studied were slightly smaller than 10 mm. Two were an 8-mm
nodule (number 25, malignant) seen on the first annual repeat
CT (new incidence nodule) and an 8.7-mm nodule (number 23,
benign) seen on the baseline study in a patient in which the
sputum cytology showed moderate to severe squamous metapla-
sia. FDG-PET scans for these two nodules were negative (one
false-negative and one true-negative). A third 8-mm nodule
(number 24, malignant) was seen in a patient with an additional
10-mm nodule (number 19, benign), which prompted the FDG-
PET study. Both nodules had negative FDG-PET scans (one
false-negative, one true-negative), but the 8-mm nodule showed
growth on follow-up CT (squamous cell carcinoma).
Altogether, 11 nodules were positive on FDG-PET, of which
nine were malignant (median SUVmax, 1.8; interquartile range,
TABLE 1. DISTRIBUTION OF NODULES ACCORDING TO
PRESENCE OF CALCIFICATION AND SIZE
NCNs (% of all NCNs) No. Calcified Nodules
 5 mm 369 (68.5)
5–10 mm 136 (25.2)
 10 mm 34 (6.3)
Total 539 (100; 55.4% of all nodules) 434 (44.6% of all nodules)
Definition of abbreviation: NCNs  noncalcified nodules.
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TABLE 2. DISTRIBUTION OF INDIVIDUALS ACCORDING
TO SIZE OF NONCALCIFIED NODULES
No. Individuals with NCNs
(% of total cohort)
 5 mm* 160 (17.6)
5–10 mm† 98 (10.7)
 10 mm‡ 33 (3.6)
Total 291 (31.9)
For definition of abbreviation, see Table 1.
* Individuals with only nodules  5 mm.
† With at least one nodule between 5–10 mm, no nodule  10 mm.
‡ With at least one nodule  10 mm.
1.6–3.1), one was benign (SUVmax, 2.3, and necrosis on FNA with
no growth on annual CT), and one was indeterminate (SUVmax,
1.2) because the patient refused further workup and was lost to
follow-up. This indeterminate nodule was excluded from the
analysis.
Fourteen nodules were negative on FDG-PET, of which four
were malignant. These four malignancies were adenocarcinomas
(two of them, numbers 15 and 25 on Table 3, had bronchoal-
veolar features in part of the tumor) and were all diagnosed in
stage IA after growth was seen on short-term follow-up CTs.
The sensitivity and specificity of FDG-PET to detect malignancy
were 69 (95% confidence interval, 41–89) and 91% (95% confi-
dence interval, 63–99), respectively. Positive and negative pre-
dictive values were 90 (95% confidence interval, 57–98) and 71%
(95% confidence interval, 52–85), respectively.
TABLE 3. NODULES STUDIED WITH F-18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY
Size on
No. CT (mm) Location CT Morphology FDG Uptake SUVmax Follow-Up Pathology Stage Result
1 20 LLL Solid Positive 2.3 Lost ? ?
2 19 RUL Solid Positive 1.2 1 yr: no growth – lost Necrosis ?
3 17.5 RUL Solid Absent No growth TN
4 17.2 LUL Solid Absent No growth TN
5 17 RUL Solid Absent No growth TN
6 16 LUL Solid Positive 1.6 — NSCLC (Squa) T1N0M0 TP
7 16 LUL Solid Absent No growth TN
8 15 RUL* Solid Positive 5.7 New nodule NSCLC (Squa) T1N0M0 TP
9 15 RLL Solid Positive 1.5 — NSCLC (Aden) T1N0M0 TP
10 14.5 LUL† Nonsolid Positive 1.6 8 months: 4 mm growth NSCLC (Aden) T1N0M0 TP
11 14 RUL Part-solid Positive 4 — NSCLC (Aden) T1N0M0 TP
12 13 LLL Solid Absent No growth TN
13 11.5 LLL Part-solid Absent 5 months: 1.5 mm growth NSCLC (Aden, 20% BAC) T1N0M0 FN
14 11 LUL Solid Positive 2.2 — NSCLC (Undif) T1N0M0 TP
15 10.5 LUL Solid Positive 2 — NSCLC (Aden) T2N0M0 TP
16 10.5 LUL† Solid Absent 12 months: 4 mm growth NSCLC (Aden) T1N0M0 FN
17 10 LUL Solid Positive 1.8 — NSCLC (Squa) T1N0M0 TP
18 10 RUL Part-solid Positive 1.6 — Lymphoepitelioma T1N0M0 TP
19 10 RUL‡ Solid Absent No growth TN
20 10 RUL Solid Absent No growth TN
21 10 RUL Solid Absent No growth TN
22 10 LLL Solid Absent No growth TN
23 8.7 RLL Solid Absent No growth TN
24 8 RUL‡ Solid Absent 15 months: 3 mm growth NSCLC (Aden) T1N0M0 FN
and change in shape
25 8 LUL* Part-solid Absent New nodule NSCLC (Aden, 80–90% BAC) T1N0M0 FN
Definition of abbreviations: Aden  adenocarcinoma; BAC  bronchoalveolar carcinoma; CT  computed tomography; FDG  F-18-fluorodeoxyglucose; FN  false
negative PET; FP  false positive PET; LLL  left lower lung; LUL  left upper lung; NSCLC  non–small cell lung cancer; RLL  right lower lung; RUL  right upper
lung; Squa  squamous cell carcinoma; SUVmax  maximum standardized uptake value; TN  true negative PET; TP  true positive PET; Undif  undifferentiated
carcinoma.
* Incidence cancers.
† Same nodule on two different FDG–positron emission tomography (PET) scans (baseline and follow-up).
‡ Two different nodules on same FDG-PET scan.
Lung Cancer Stages
Lung cancer was detected in 14 (13 non–small cell lung cancers
and 1 small cell lung cancer) of 911 individuals entered in the
study. Eleven of the 13 non–small cell lung cancers and one small
cell lung cancer were detected on the baseline study (prevalence,
1.32%). Of 424 individuals who have completed at least one
annual repeat CT, two were diagnosed with non–small cell lung
cancer (incidence, 0.47%). Of the prevalence cancers, 10 (86%)
were stage IA (T1N0M0) and one was stage IB (T2N0M0). The
only small cell lung cancer was diagnosed in stage T3N3M0. The
incidence cancers were both detected in stage IA (T1N0M0).
Considering all cancers, 13 of 14 (92.8%) were diagnosed in
stage I.
Invasive Procedures and Surgery
There were no preoperative surgical biopsies performed. Six
preoperative percutaneous FNAs were performed on four PET-
positive nodules and two growing PET-negative nodules. Four
of these were positive for malignancy and two were negative.
One negative FNA (PET-positive) was followed up with a yearly
CT showing no growth (false-positive PET). The possibility that
this individual actually has a slow-growing cancer cannot be
ruled out, although this is unlikely in view of the lack of growth.
The other negative FNA (PET-positive) was inadequate because
of a pneumothorax. This individual had an intraoperative biopsy
showing a malignancy. The patient with small cell lung cancer
was diagnosed with a bronchoscopy. The rest of the patients
were diagnosed with intraoperative biopsies.
All patients with non–small cell lung cancer (prevalence
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and incidence) underwent surgery. Eleven of 13 (84.6%) had
lobectomies and two (15.4%) had wedge resections because of
chronic obstructive pulmonary disease.
Spirometry
Of 834 subjects who had spirometry at baseline, 220 (26.4%)
had an FEV1/FVC of less than 70%. Of these, 113 (51.4%) had
an FEV1 of less than 80% (mild airflow obstruction), 90 (40.9%)
had an FEV1 of less than 80 but at least 50% (moderate airflow
obstruction), 14 (6.4%) had an FEV1 of less than 50 but at least
30% (severe airflow obstruction), and three (1.4%) had an FEV1
of less than 30% (very severe airflow obstruction). Of the 14
patients with non–small cell lung cancer, 11 (79%) had airflow
obstruction (FEV1/FVC  70%). Six had mild, four had moder-
ate, and one had severe airflow obstruction.
DISCUSSION
Similar to recent reports (9, 20–22), this study confirms that a
low-dose spiral CT–based protocol for early detection of lung
cancer is useful in leading to early stage diagnosis in a high
proportion of cases and may increase the chances for cure. Fur-
thermore, this study shows that a carefully followedmultidiscipli-
nary diagnostic algorithm that includes FDG-PET minimizes
unnecessary invasive procedures for benign lesions, without re-
sulting in missed cancers caused by false-negative PET scans.
Lung cancer is one of the leading causes of death in the world.
It is the most common cancer in many countries and, because
most patients are diagnosed in late stages, it is also the most
lethal (1–3). Less than 20% of individuals suffering this disease
are diagnosed in stages in which curative surgery is an option (2).
Survival rates for early-stage disease are quite high, approaching
80% in some series, but overall 5-year survival rates are approxi-
mately 15% (2). Five-year survival rates for patients who have
already survived 2 years (conditional survival) remain signifi-
cantly higher for those diagnosed in early stages, stressing the
importance of early diagnosis (23).
Lung cancer screening with low-dose CT has shown to be
effective in diagnosing lung cancer in the early stages. In ELCAP,
89% of lung cancers detected in the prevalence phase of the
trial were diagnosed in stages I and II (9). In other screening
trials, the proportion of cancers diagnosed in stages I and II
varies between 75 and 90% (10–14). Whether this will result in
a reduction in mortality from lung cancer has not been answered
yet, and is being addressed in several trials underway. However,
it is clear from a clinical point of view that lung cancer diagnosed
and treated in early phases has a much better prognosis. Despite
the fact that earlier screening trials with chest radiographs and
sputum cytology failed to show a reduction in mortality, the
results obtained from CT screening trials published thus far,
and those presented herein, are strong enough to warrant more
research in the field.
One of the major concerns regarding lung cancer screening
with spiral CT is the rate of false-positive tests resulting in poten-
tially harmful workups for benign diseases. The prevalence of
noncalcified nodules on baseline low-dose spiral CT in different
trials ranges between 19 and 69% (9, 12, 20–22). Limiting further
workup to nodules of 5 mm or more has been shown to be
appropriate by Henschke and coworkers (24) in a recent study
reviewing diagnoses of lung cancer in a CT screening trial ac-
cording to size. In a population of 2,897 participants, lung cancer
was diagnosed only in individuals with nodules of at least 5 mm
in diameter. Of 378 participants with the largest noncalcified
nodule less than 5 mm in diameter, none was diagnosed with a
malignancy. In our series, 32% of participants had noncalcified
nodules of any size, but only 14% required further workup be-
cause of the presence of at least one noncalcified nodule of 5 mm
ormore (positiveCT scans).Among this group of individuals, the
majority had small nodules between 5 and 10 mm. Following
these nodules with short-term follow-up CTs for detection of
growth results in a low rate of invasive procedures for benign
lesions. Larger nodules or nodules that show growth on follow-
up CTs, all of which are more likely to be malignant, pose a
more difficult problem and are more likely to result in unneces-
sary invasive procedures. Our findings suggest that the addition
of FDG-PET to the protocol does not eliminate the risk of
unnecessary invasive procedure completely, but may reduce it
to a minimum. Excluding the patient with one nodule that was
positive on FDG-PET but who was lost to follow-up, the speci-
ficity and positive predictive value of FDG-PET in our series
was 91 and 90%, respectively. What price, in terms of invasive
procedures or even surgical interventions for benign lesions, is
acceptable in screening protocols remains to be seen. In this
series, no surgical intervention was done for a benign lesion, but
one benign lesion did undergo an FNA. The risk for complica-
tions and the anxiety generated in the workup of benign lesions
has to be considered as endpoints in future studies. On the other
hand, using FDG-PET, the diagnosis of cancer in 9 of 13 patients
was achieved 3 months earlier than if obtained by short-term
follow-up CT. The implications this might have in terms of over-
all prognosis are unknown.
Although FDG-PET had a positive influence on the diagnos-
tic management of 19 of 25 cases, the sensitivity and negative
predictive value of FDG-PET for the diagnosis of malignant
nodules in this population was 69 and 71%. The overall sensitiv-
ity of FDG-PET for the diagnosis of pulmonary malignancies
greater than 1 cm is over 95% (25). However, recent studies
show that for pulmonary malignant nodules of less than 1 cm in
size, the sensitivity of FDG-PET is very low (26). Four malignant
nodules in our series did not show any FDG uptake. Two were
smaller than 1 cm (8 mm), and two only slightly larger (10.5 and
11.5 mm). Furthermore, all four false-negative nodules were
adenocarcinomas and two had a nonsolid component on the CT
and bronchoalveolar features on the histologic analysis (Table
3, nodule numbers 13 and 25). These characteristics (adenocarci-
noma, part-solid component, and bronchoalveolar carcinoma)
have all been reported by others as causes of false-negative
nodules onFDG-PET scans (26). Therefore, it is the combination
of FDG-PETwith a short-term follow-upCT for negative studies
that makes the screening algorithm useful. In addition, although
the protocol calls for percutaneous FNAs of suspicious nodules
(those 10 mm or smaller nodules that grow), the results of this
study support FDG-PET as a noninvasive substitute if caution
in following up negative studies is taken. The optimal interval
between a negative FDG-PET and a follow-up CT to detect
growth remains to be determined. It may be longer that the 3-
month interval selected in this protocol, thus decreasing the
potential hazards caused by radiation, as well as the costs of the
algorithm.
SUVs may provide numeric thresholds to differentiate malig-
nant and benign lesions, but in our series, visual assessment of
FDG-PET scans classified the indeterminate noncalcified pulmo-
nary nodules better. Visual analysis of FDG-PET scans was
performed for diagnosis because it has been shown that SUV
methodology is less straightforward than has often been assumed
(27). Furthermore, the SUV of a lesion on FDG-PET decreases
when the diameter is smaller than twice the spatial resolution
of the system, which is 7 to 8 mm for our BGO scanner. In our
study, if only lung nodules with an SUVmax greater than 2
would have been considered positive, FDG-PET would have
contributed to establish the proper diagnosis in 14 cases instead
of the 19 cases correctly diagnosed with visual analysis. The
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sensitivity and the negative predictive value of FDG-PET for
the diagnosis of malignant nodules would have decreased to 23
and 52%, respectively. The efficiency of a screening program
will depend largely on the pretest probability (prevalence) of
having the disease. The higher the prevalence, the lower the risk
of false-positive results. The prevalence will be higher as the
inclusion of individuals in the screening program becomes more
selective, focusing on higher risk. One future possibility is the
use of biomarkers, not only for early detection but for risk
stratification as well (28). From a clinical point of view, the
presence of airways disease may be important for risk stratifica-
tion. In this study, 79% of the patients with lung cancer had
airflow obstruction by GOLD criteria (19). Therefore, limiting
enrollment to individuals with evidence of airflow obstruction
might enhance efficiency. Related to this finding is the fact that
30% of the participants showed evidence of airflow obstruction.
A recent preliminary randomized controlled lung cancer screen-
ing trial, in which patients were classified according to the pres-
ence of airways disease into high-risk (airflow obstruction) and
moderate-risk (no airflow obstruction) individuals, showed that
the probability of finding noncalcified nodules is significantly
higher (40 vs. 22%) in patients with airways obstruction (29).
This also raises the issue of whether a screening program for
lung cancer might be useful for screening other important dis-
eases, such as chronic obstructive pulmonary disease, which is
the fifth leading cause of death worldwide (30).
This report and others point out one very important aspect.
Early lung cancer detection is complex and requires a multidisci-
plinary approach. With the data available to date, lung cancer
screening, although promising, still requires intensive research
before wide implementation. But it is quite clear that the diagno-
sis and management of lung cancer are due for a change. The
need for a new staging system that addresses smaller lung cancers
is emerging. Data from Europe and the United States strongly
suggest that the current size threshold for staging lung cancers
(i.e., 3 cm) is not adequate and support the notion that detecting
small-volume lung cancers provides a better chance for cure.
The Spanish Bronchogenic Carcinoma Co-operative Group has
found that classifying patients into four groups according to
tumor size (0–2 cm, 2.1–4 cm, 4.1–7 cm, and  7 cm) better
predicted prognosis (31). In the United States, using the 2003
Surveillance, Epidemiology, and EndResults, or SEER, registry,
Wisnivesky and coworkers (32) showed that 12-year survival
among patients with stage I lung cancer who had undergone
surgical resection was inversely proportional to the initial tumor
size.
In conclusion, early detection of lung cancer after a carefully
designed low-dose spiral CT–based protocol with the addi-
tion of FDG-PET for nodules of 10 mm or more, or for smaller
( 7 mm) growing nodules, is possible. The addition of FDG-PET
to the protocol may reduce unnecessary invasive procedures to
a minimum without resulting in missed cancers. This strategy
may improve chances for cure because epidemiologic data
strongly suggest that the prognosis of lung cancer is significantly
better when diagnosed in early stages.
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